CHRONIC SPONTANEOUS URTICARIA (CSU)
Clinical trials for CHRONIC SPONTANEOUS URTICARIA (CSU) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC SPONTANEOUS URTICARIA (CSU) trials appear
Sign up with your email to follow new studies for CHRONIC SPONTANEOUS URTICARIA (CSU), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New shot could tame stubborn hives that antihistamines Can't stop
Disease control Recruiting nowThis study tests an experimental injection called CM512 for people with chronic spontaneous urticaria (CSU) — long-lasting hives with itching and welts that don't go away with regular allergy pills. About 48 adults will receive either CM512 or a placebo to see if the drug reduces…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated May 26, 2026 08:40 UTC
-
Biosimilar switch study aims to keep chronic conditions in check
Disease control Recruiting nowThis study follows 225 adults with chronic spontaneous urticaria (long-term hives) or severe allergic asthma whose disease has been stable for at least 3 months on the original omalizumab. Their doctor has decided to switch them to a biosimilar version called Omlyclo®. The main g…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Sponsor: Celltrion HealthCare France • Aim: Disease control
Last updated May 26, 2026 08:28 UTC
-
New drug showdown: can remibrutinib beat dupilumab for stubborn hives?
Disease control Recruiting nowThis study tests two experimental drugs, remibrutinib (a pill) and dupilumab (an injection), in adults with chronic hives that antihistamines can't control. About 400 participants will receive one of the treatments for 4 weeks to see which works faster at reducing itch and hives.…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
New hope for chronic hives sufferers: drug trial targets itch and welts
Symptom relief Recruiting nowThis study tests an experimental drug called ICP-332 for people with moderate to severe chronic spontaneous urticaria (long-lasting hives) that antihistamines don't fully control. About 344 adults aged 18 to 75 will receive either the drug or a placebo to see if it reduces itchin…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Phase: PHASE2, PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Symptom relief
Last updated May 26, 2026 08:19 UTC
-
New hope for chronic hives sufferers: experimental drug lesigercept in human trials
Symptom relief Recruiting nowThis study tests a new drug called lesigercept for people with chronic spontaneous urticaria (long-term hives) that antihistamines don't fully control. About 150 adults will receive either the drug or a placebo for 12 weeks to see if it reduces itching and welts. The goal is to f…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Phase: PHASE2 • Sponsor: Yuhan Corporation • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC
-
Scientists probe hidden IgE shapes to unlock allergy mysteries
Knowledge-focused Recruiting nowThis study aims to understand different forms of the IgE protein in healthy people and those with allergies, chronic hives, anaphylaxis, mastocytosis, and other immune conditions. Researchers will collect blood samples from 200 adults to compare these IgE variants. The goal is to…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA (CSU)
Sponsor: KU Leuven • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC